Insulet
Insulet Corporation, commonly known for its innovative Omnipod® Insulin Management System, is a leading player in the diabetes care industry. Headquartered in the United States, Insulet operates primarily in North America and Europe, focusing on developing advanced insulin delivery solutions. Founded in 2000, the company has achieved significant milestones, including the launch of its tubeless insulin pump, which revolutionised diabetes management for many patients. Insulet's core product, the Omnipod, stands out due to its unique design that offers a wireless, waterproof, and discreet insulin delivery system. This innovative approach has positioned Insulet as a market leader, recognised for enhancing the quality of life for individuals with diabetes. With a commitment to continuous improvement and patient-centric solutions, Insulet remains at the forefront of diabetes technology, driving advancements that empower users to manage their condition effectively.
DitchCarbon Score
How does Insulet's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Insulet's score of 39 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Insulet's reported carbon emissions
In 2024, Insulet reported total greenhouse gas emissions of approximately 13,830,000 kg CO2e, comprising 1,383,000 kg CO2e from Scope 1 and 11,467,000 kg CO2e from Scope 2 emissions. This marks a notable increase in emissions compared to 2023, where the company recorded about 1,316,000 kg CO2e in Scope 1 and 3,977,000 kg CO2e in Scope 2, totalling approximately 5,293,000 kg CO2e. Insulet has made significant strides in reducing its carbon footprint, achieving a reduction of about 19% in Scope 1 emissions from 2020 to 2021. The company is committed to a net-zero transition, with plans to establish targets for greenhouse gas emissions reduction and increase the use of renewable energy in its operations by 2030. This commitment extends to both Scope 1 and Scope 2 emissions, with ongoing investments in renewable energy and sustainable practices, including the development of a new manufacturing facility in Malaysia aimed at achieving Green Building Index (GBI) and Leadership in Energy and Environmental Design (LEED) Silver certifications. Insulet's climate strategy reflects a long-term vision, with initiatives designed to minimise environmental impact and enhance sustainability across its operations. The company is actively working on a blueprint for achieving net-zero emissions by 2050, reinforcing its dedication to environmental stewardship in the healthcare sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 1,709,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 3,761,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Insulet is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
